Welcome to our dedicated page for Caring Brands news (Ticker: CABR), a resource for investors and traders seeking the latest updates and insights on Caring Brands stock.
Caring Brands, Inc. reports developments tied to its OTC and cosmetic wellness consumer products business. Company news centers on product commercialization, intellectual property, and distribution rights, including the Hair Enzyme Booster technology, U.S. patent coverage for enzyme-based hair-follicle methods, and the exclusive global license to manufacture, market, and distribute Emesyl for OTC nausea relief.
Recurring updates also cover capital actions and public-company status, including the company's Nasdaq listing, registered and private financing activity, and working-capital plans. Its product categories include hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, jellyfish sting protective suncare, and women's sexual wellness products.
Caring Brands (Nasdaq:CABR) and SanPellegrino Cosmetics signed a revised, multi-territory licensing deal for Photocil and Hair Enzyme Booster, effective May 21, 2026.
The five-year agreement, with automatic annual renewal, extends SCPL’s rights from India into LATAM, Russia, Australia and New Zealand, leveraging existing Asian partnerships and clinical validation in dermatology and hair growth.
Caring Brands (NASDAQ: CABR) announced issuance of two U.S. patents in January 2026 covering methods and compositions that increase sulfotransferase enzyme activity for its Hair Enzyme Booster technology. The patents broaden exclusive IP around enzyme-based topical hair loss treatments and support ongoing commercialization in the U.S. and via international licensees.
Caring Brands (Nasdaq: CABR) entered an exclusive worldwide license with Itonis to manufacture, market, and distribute Emesyl, an over-the-counter nausea relief product, effective Jan 5, 2026.
Under the agreement Caring Brands will assume global manufacturing, marketing, sales strategy, and distribution while Itonis will supply technical, formulation, historical sales, and IP information. The deal includes a royalty on future net sales and potential equity earn‑outs tied to revenue milestones. The release cites a QY Research market projection of USD 6.23 billion for nausea treatments in 2025. Caring Brands said it will provide further updates on timelines, manufacturing progress, and commercial rollout as initiatives advance.
Caring Brands (NASDAQ:CABR) closed an underwritten U.S. public offering of 1,000,000 shares at a public offering price of $4.00 per share for aggregate gross proceeds of approximately $4,000,000, before underwriting discounts and offering expenses.
The shares began trading on the Nasdaq Capital Market on November 13, 2025. The underwriter has a 45-day option to purchase up to an additional 150,000 shares at the public offering price, less discounts and commissions. The company intends to use net proceeds for general working capital, marketing and sales, and repayment of certain debt. Registration on Form S-1 (File No. 333-289767) was declared effective on October 30, 2025. D. Boral Capital LLC acted as sole underwriter.
Caring Brands (NASDAQ:CABR) priced an underwritten public offering of 1,000,000 common shares at $4.00 per share for gross proceeds of approximately $4,000,000, with a 45-day underwriter option to buy up to 150,000 additional shares. The offering is expected to close on November 14, 2025. The company received approval to list common shares on the Nasdaq Capital Market, with trading expected to begin on or around November 13, 2025, at which point shares will cease trading on the OTCQB. Proceeds are intended for general working capital, marketing and sales of proprietary products, and repayment of certain debt. The S-1 was declared effective on October 30, 2025.